ERBB2 and cholangiocarcinoma: The KAMELEON trial (phase II, NCT02999672), which investigated trastuzumab emtansine in patients with HER2-positive advanced CCA, reported recruitment difficulties, resulting in no representative data being generated from the study regarding the treatment of CCA with trastuzumab emtansine.